Assessing the Risk of CMV Reactivation and Reconstitution of Antiviral Immune Response Post Bone Marrow Transplantation by the QuantiFERON-CMV-Assay and real time PCR

Allogenic hematopoietic stem cell transplantation (alloHSCT) recipients are at significant risk for infectious complications [1,2]. The human cytomegalovirus (CMV) is a life-long persisting virus with a prevalence between 45 and 100% in the general adult population [3]. Recurrent reactivations in healthy individuals are common, but occur usually in the absence of symptoms [4]. In immunocompromised individuals like alloHSCT recipients, CMV reactivation is associated with severe and fatal complications.

Source: Journal of Clinical Virology - January 9, 2018 Category: Virology Authors: Adalbert Krawczyk, Jessica Ackermann, Birgit Goitowski, Rudolf Trenschel, Markus Ditschkowski, J örg Timm, Hellmut Ottinger, Dietrich W. Beelen, Nico Grüner, Melanie Fiedler Source Type: research